Bezlotoxumab (Zinplava)

Covered: one dose of bezlotoxumab (Zinplava) to reduce recurrence of C. difficile infection only for patients currently receiving antibacterial treatment for CDI who are at high risk for recurrence; off‑label uses are excluded and prior receipt of Zinplava disqualifies approval. Key requirements: documentation of CDI diagnosis, current antibacterial therapy, high‑risk factors, no prior Zinplava receipt, and if the patient has congestive heart failure a clinical justification that expected benefit outweighs risk.

"Indicated to reduce recurrence of Clostridium difficile infection in individuals who are receiving antibacterial drug treatment for Clostridium difficile infection and are at a high risk for Clostr..."

Sign up to see full coverage criteria, indications, and limitations.